Full Length Research Paper

The effect of metformin and exercise on serum lipids, nitric oxide synthase and liver nitric oxide levels in streptozotocin-nicotinamide induced diabetic rats

Fahrettin Akyuz1, Neslihan Tekin1*, Ozlem Aydin1, Halide Edip Temel2 and Burhanettin Isikli3

1Department of Medical Biochemistry, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
2Department of Biochemistry, Faculty of Pharmacy, Anadolu University, Eskisehir, Turkey.
3Department of Public Health, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.

Accepted 11 January, 2012

The objective of this study was to determine the effects of metformin treatment and exercise intervention on lipid metabolism, nitric oxide (NO), nitric oxide synthase (NOS), glucose levels in streptozotocin-nicotinamide (STZ-NA) induced diabetic rats. Male wistar rats were used to conduct the study and they were divided into five groups of 8 rats in each. These groups are: Control group, diabetes group (STZ-NA), diabetes and metformin (DMet) group, diabetes and exercise (DE) group, and diabetes + exercise + metformin (DEMet) group. The STZ-NA induced diabetic rats were used as a model of type 2 diabetes. Metformin was orally administered to rats. For exercise intervention, rats were forced to run in a running wheel for 10 min each day (20 m/min/day). At the end of experimental period, blood glucose, glycated hemoglobin (HbA1c) levels, plasma lecithin:cholesterol acyltransferase (LCAT) levels, serum triglyceride (TG), cholesterol, high density lipoprotein (HDL), Apo A-I, NOS and liver NO levels were determined. Metformin caused beneficial changes in blood glucose, HbA1c levels, and HDL in type 2 diabetic rats. Both administration of metformin and exercise intervention independently caused beneficial changes in blood glucose. However, the surprising result found was that exercise intervention did not optimize the result of metformin treatment. The other finding of this study was that exercise intervention increased cholesterol and NOS level but exercise combined with metformin was not better than exercise alone. Thus, it appears from the present study that metformin and exercise combination has no effect.

Key words: Diabetes, exercise, lecithin:cholesterol acyltransferase (LCAT), metformin, nitric oxide synthase.

INTRODUCTION

Diabetes mellitus is one of the most widespread disease in both developed and developing countries. Type 2 diabetes is based mainly on decreased insulin responsiveness due to the down-regulation of hormone receptors on peripheral cells, leading to hyperglycemia (Hrabak et al., 2006). Treatment of hyperglycaemia in type 2 diabetes mellitus (T2DM) is necessary to relieve acute symptoms and to reduce the risk of chronic vascular complications (Bailey, 2011). Lifestyle modifications including diet and exercise are often insufficient for reducing glucose and weight, and most patients with type 2 diabetes will require pharmacotherapy to treat their hyperglycemia (Blevins, 2010).

Exercise is recommended for the treatment of type 2 diabetes to assist in weight management and glucose control and also it is shown that, it increases whole-body insulin sensitivity. Exercise has potential to improve the glucose lowering effect of oral antihyperglycemic therapy (Tang and Reed, 2001). Metformin belongs to biguanide family, used as an orally active antihyperglycemic drug in the treatment of human type 2 diabetes (Saravanan and Pari, 2006). Metformin controls hyperglycemia via ameliorating insulin sensitivity and decreasing insulin
levels and it also regulates lipid profiles (Katakam et al., 2000). It is reported that metformin has antioxidant activity which is independent of its effect on insulin activity. Furthermore, Sarotreta et al. (2005) mentioned that metformin increases NO activity without increasing NO expression in n-STZ diabetic rats (Majithiya and Balaranan, 2006). NO is an important cellular regulator (Kingwell, 2000). The production of NO from L-arginine is synthesized by a family of enzymes called nitric oxide synthases (NOS) (Gao, 2010; Ozbayer et al., 2011). It is known that NO plays important roles on muscle contractility (smooth muscle, cardiac, and skeletal muscle), platelet aggregation, metabolism (glucose, lipid, and amino acid metabolism), neuronal activity, and immune responses (Gao, 2010). Moreover, there is increasing evidence that NO is an important haemodynamic and metabolic regulator during the physical activity (Kingwell, 2000).

Studies also emphasize that lower NO production causes hyperlipidemia (Zand et al., 2011; Ma et al., 2011; Goto et al. 1999). Hyperlipidemia is one of the metabolic complications of both clinical and experimental diabetes. Treatment of hyperlipidemia in diabetes involves improving of glycemic control, exercise and the use of lipid lowering diets and drugs (Saravanan and Pari, 2006).

Although metformin is widely used in the treatment of type 2 diabetes, its mechanism of action is unclear. There are few reports on short-term effects of the drug. Also the relationship between NO synthesis and the metabolism of lipid and glucose is incomplete. The aim of this study was to evaluate the effects of short-term metformin treatment and exercise intervention on lipid metabolism, lecithin:cholesterol acyltransferase (LCAT), NO, NOS and glucose levels in Streptozotocin-Nicotinamide induced type 2 diabetes.

MATERIALS AND METHODS

Animals

Three to four months old male Wistar rats (n=40) weighing 200 to 280 g were supplied from the Eskisehir Osmangazi University Experimental Research Center. Rats were housed in polycarbonate cages in a temperature (21±2°C) and humidity (45 to 55%) controlled room. They were fed with a standard rat chow (Oguzlar Yem, Eskisehir, Turkey) and allowed to drink water ad libitum. This study was approved by Eskisehir Osmangazi University Institutional Local Animal Care committee. Animals were divided into five groups of 8 rats in each; (I) control, (II) diabetes (STZ+NA) group, (III) diabetes and exercise (DE) group, (IV) diabetes and metformin (DMet) group, and (V) diabetes + exercise + metformin (DMet) group.

Experimental design

At the beginning of the experimental period, tail blood samples were taken for blood glucose determination by using glucometer (Accutrend, Boehringer Mannheim, Germany). Rats in each group except control group were given intraperitoneally (i.p) 290 mg/kg of nicotinamide dissolved in saline. After 15 min, they were given intraperitoneally 60 mg/kg STZ dissolved in citrate buffer (pH 4.5) (Maisello et al., 1998).

After administration of STZ and NA, fasting blood glucose levels were determined every week from tail veins of all animals during the next 5-week period using glucometer (Accutrend, Boehringer Mannheim, Germany). Fasting blood glucose levels were measured. The animals that showed stable hyperglycemia (range, 115 to 120 mg/dl) were used for experiments as diabetics. After acclimatization period of 5 weeks following the induction of diabetes, the experimental period lasted for six days.

(I) Control group: Any medication or treatment was given to control group.

(II) Diabetes (STZ+NA group: The diabetes group did not receive any medication.

(III) Diabetes and exercise (DE) group: The DE group did not receive any medication. Instead, they were forced to run in a running wheel at a speed of 20 m/min for 10 min each day.

(IV) Diabetes and metformin (DMet) group: The DMet group received metformin orally at 50 mg/kg for the first day and adding of 50 mg/kg metformin for each day and finally for the last day of the experimental period the rats received 300 mg/kg metformin orally (Katakam et al., 2000).

(V) Diabetes + exercise + metformin (DMet) group: DMet group received metformin orally at 50 mg/kg for the first day and adding of 50 mg/kg metformin for each day and finally for last day of the experimental period the rats received 300 mg/kg metformin orally (Katakam et al., 2000) similar to DMet group. Additionally, they were forced to run in a running wheel at a speed of 20 m/min for 10 min each day (Copp et al., 2010).

At the end of experimental period, the tail blood samples were taken for blood glucose determination for the second time. Intracardiac whole blood samples were collected, under ether anesthesia, into two different tubes. First tubes were centrifugated at 3500 g for ten minutes to separate the serum and used for the determination of lipid profiles. The second tubes including EDTA, used firstly for the determination of HbA1c and then used for lecithin cholesterol acyltransferase (LCAT) assay. HbA1c was measured by using Roche-Hitachi kit via Hitachi 911 Analyzer. After the collection of blood samples, rats were sacrificed. Under aseptic conditions, a midline incision was made and their livers were removed.

Liver nitrite

NO as a free radical is relatively unstable in oxygenated solutions where it rapidly and spontaneously reacts with molecular oxygen to yield a variety of nitrogen oxides. It was demonstrated that the only stable products formed by spontaneous decomposition of NO in oxygenated solutions are nitrates and nitrates, thus they were measured as indicators for NO production (El-Mahmoudy et al., 2005). Liver tissues were homogenized in Tris-HCl buffer (5 mM containing 2 mM EDTA, pH 7.4). The supernatants were prepared by centrifugation at 2000 g for 5 min (Futter et al., 2001). Nitrate in supernatants was assayed by a modification of cadmium (Cd)- reduction method; the produced was nitrite determined by diazotization of sulfanilamide and coupling to naphthylethylenediamine. After samples were deproteinized by Somogyi reagent, the nitrate was reduced by Cu-coated Cd in glycine buffer at pH 9.7 (2.5 to 3 g of Cd granules for a 4 ml reaction mixture). Nitrite was then measured spectrophotometrically by adding of the 2.5 ml of deproteinized sample, 1 ml of H2O, 1 ml of sulfanilamide solution and 1 ml of N-naphthylethylenediamine solution. Absorbances were determined at 545 nm after 20 to 60
min of incubation. The concentration of nitrite levels in the serum was determined by using standard curve, which was constructed by using sodium nitrite as the standard (Cortas and Wakid, 1990). The amount of protein was evaluated by using biureth method (Layne et al., 1957).

**NOS assay**

NOS level in the serum was measured by using nitric oxide assay kit (BIOXYTECH®, Oxis International, Inc, Portland, OR, USA, Cat. No: 22113) via Alpha Prime Multiplate ELISA test Analyzer (SFR1/AES Laboratoire, France).

**Lecithin: Cholesterol acyltranferase assay**

LCAT activity in plasma was measured by the colorimetric method described by Nagasaki and Akanuma (1977). Synthetic dipalmitoyl lecithin solution was added to the incubation medium and then the change in free cholesterol content following the incubation period was analyzed by a combined enzymatic method by using cholesterol oxidase and peroxidase.

**Serum lipids**

Lipid profiles (serum triglyceride, TG, cholesterol, high density lipoprotein, HDL, Apo A-I) were measured by using Roche-Hitachi kit via Roche Diagnostic Modular Analyzer.

**Statistical analysis**

Data were expressed as mean ± standard error. Statistical Package for the Social Sciences (SPSS) standard version 13.0 for Windows was used to evaluate the data. Statistical analyses were performed by one-way analysis of variance (ANOVA) test. Groups were compared by using Fisher LSD test.

**RESULT**

The glucose levels in tail venoz samples taken at the beginning and at the end of the study were similar to that of the control rats (p>0.05). Blood glucose levels were increased significantly in STZ-NA group compared to the controls (p<0.001). On the other hand, decreases in all of the intervention groups (DMet, DE, DEMet) according to the STZ-NA group (p<0.001, p<0.05, p<0.01 respectively) (Table 1).

HbA1c level was increased significantly in STZ-NA group as compared to healthy controls, (p<0.001). Treatment with metformin was ameliorated HbA1c level in DMet group versus STZ-NA, (p<0.01). Cholesterol increased significantly in STZ-NA group compared to control group (p<0.001). In the DE and DEMet group, cholesterol level was decreased significantly compared to STZ-NA group (p<0.001). TG level in STZ-NA group did not change significantly compared to control group, (p>0.05). Apo A-I and HDL levels was decreased in STZ-NA group compared to control group, (p<0.001 and p<0.001, respectively). Metformin treatment increased HDL level in DMet and DEMet groups compared to STZ-NA group (p<0.001 and p<0.001 respectively) (Table 1).

Plasma LCAT activity in the STZ-NA group was lower than in the control group (p<0.001). In plasma LCAT activity, there was no difference between STZ-NA group and other groups (p>0.05) (Table 2). Liver NO was decreased significantly in STZ-NA group compared to control group, (p<0.001). In liver NO, there was no difference between STZ-NA group and other groups. STZ-NA group showed a reduced NOS activity compared to control group (p<0.01). It was observed that NOS activities in DE and DEMet groups was increased significantly as compared to STZ-NA group, (p<0.001 and p<0.005, respectively) (Table 2).

**DISCUSSION**

This is the first study giving information about measured NO, NOS and LCAT activities in STZ-NA induced diabetic rats and also including data for metformin, exercise and combined exercise-metformin treatment in STZ-NA induced diabetic rats. In recent years, STZ and nicotinamide are used to induce type 2 diabetes mellitus in rats. The diabetic animal model induced by administration of STZ and nicotinamide shows hyperglycemia and reduced glucose intolerarance, but still able to secrete insulin in the presence of glucose (Li et al., 2011). In our study, blood glucose levels were increased in STZ-NA group compared to the controls although there were no differences between the glucose levels of the control rats at the beginning and at the end of the study. The same increase is reported by many researchers (Saravanan and Pari, 2006; Novelli et al., 2001; Novelli et al., 2004).

In type 2 diabetes mellitus, increased physical activity decreases fasting plasma glucose and insulin levels, suggesting increased insulin sensitivity (Lehman et al., 2001). In our study, serum glucose levels decreased after exercise intervention in DE group (p<0.05). This result supports Reaven's results demonstrating "exercise decreases glucose concentrations in animal models of type 2 diabetes" (Reaven and Chang, 1981). The reduction of glucose levels in exercise group may be associated with a compensatory function in pancreatic β-cells. In a swim exercise model of type 2 diabetic rats, regular exercise increased the rates of β-cell proliferation and β-cell mass compared with sedentary control animals (Yi et al., 2009). Also Choi et al. (2006) showed that exercise ameliorates glucose homeostasis by improving β-cell function and mass as well as reducing insulin resistance in 90% of pancreatectomized rats. Like insulin, exercise increases glucose uptake into skeletal muscle. Exercise increase glucose uptake into skeletal, via a pathway independent to that of insulin. Glucose can not passively diffuse into a cell and must be transported through the cell membrane by glucose transporters.
(GLUT4). GLUT4 is the major glucose transporter isoform expressed in skeletal muscle, and has a large capacity to increase glucose transport across the cell membrane through facilitative diffusion. The mechanism(s) through which exercise stimulates GLUT4 translocation and glucose uptake appear to arise from local factors within skeletal muscle such as NO. There is building evidence that NO is important for the regulation of glucose uptake into skeletal muscle of rodents and humans during contration/exercise independent of blood flow, and likely to be associated with signaling GLUT4 translocation (Merry and McConell, 2009). Exercise, from a metabolic perspective, may promote increased plasma arginine levels by increasing amino acid mobilization from skeletal muscle, thus normalizing cellular production of NO (Newsholme et al., 2010).

Current therapeutic strategies for type 2 diabetes involve insulin and oral antidiabetic agents via stimulating pancreatic insulin secretion, reducing hepatic glucose production, delaying digestion and absorption of intestinal carbohydrate or improving insulin action (Tahara et al., 2008). In our study, we used metformine as antidiabetic agent. It has been reported that metformin has multiple activities, including suppression of hepatic glucose production and improvement of peripheral insulin sensitivity, in type 2 diabetic patients. So, it reduces hyperglycemia (Tang and Reed, 2001; Saravanan and Pari, 2006; Okamoto et al., 2008; Anurag and Anuradha, 2002). In the present study, we observed that metformin rapidly decreased blood glucose levels. In our study, serum glucose levels of the intervention groups (Groups III, IV and V) were significantly lower than the STZ-NA group (Group III) (p<0.05, p<0.001, p<0.01, respectively).

In our study, metformin treatment reduced HbA1c levels, similar to the decrease in blood glucose levels. On the other hand, we did not observe the same decrease in both of the DE group (Group III) and DEMet groups (Group V). This can be explained by the theory of Valeri et al. (2004) describing that, levels of HbA1c are probably determined by factors other than glucose metabolism, including the rate of haemoglobin glycation and red cell survival. There is need of new studies regarding the correlation between exercise and HbA1c levels.

Diabetes is associated with profound alterations in plasma lipid and lipoprotein profile. Hyperlipidemia is recognized by elevated levels of cholesterol, TG and phospholipids; and changes in lipoprotein composition (Saravanan and Pari, 2006). In our study, STZ-NA application significantly increased cholesterol and TG levels while it decreased HDL levels. The increase in serum lipids in the diabetics is mainly due to the increased mobilization of free fatty acids from peripheral deposit, since insulin inhibits hormone sensitive lipase. Treatment of hyperlipidemia in diabetes involves improving glycemic control, exercise and drugs (Tang and Reed, 2001). It is reported that exercise (Lampman and Schteingart, 1991), and metformin (Saravanan and Pari, 2006; Katakam et al., 2006) each have beneficial effects on lipid regulation in type 2 diabetes. In our study, HDL levels increased by metformin treatment. This increase also had been observed in DEMet group (Group V). While, exercise, had no effect on HDL levels. The increase in combined group could be explained by the

---

**Table 1. Blood glucose, HbA1c and some lipid profiles of the studied groups.**

| Variable                  | Control       | STZ-NA       | D Met       | DE           | DEMet        |
|---------------------------|---------------|--------------|-------------|--------------|--------------|
| Glucose (mg/dl)           | 82.6±8.3      | 120.25±2.6***| 104.25±7.0### | 113.25±6.1†  | 110.50±3.7## |
| HbA1c (mg/dl)             | 3.61±0.4      | 4.69±0.4***  | 3.90±0.5##  | 4.26±0.4##   | 4.26±0.6##   |
| Apo A-I (mg/dl)           | 3.30±0.8      | 1.53±0.2***  | 1.54±0.2##  | 1.21±0.4##   | 1.34±0.4##   |
| HDL (mg/dl)               | 52.00±4.3     | 44.50±5.1**  | 54.25±5.1### | 46.13±3.1##  | 47.75±6.1### |
| Cholesterol (mg/dl)       | 54.13±8.6     | 71.38±6.3*** | 67.50±5.3## | 59.38±4.1### | 57.13±5.3### |
| TG (mg/dl)                | 60.50±7.2     | 67.38±2.9##  | 61.63±8.3## | 62.88±1.4##  | 60.00±4.8##  |

*** P<0.001 versus control group, ** P<0.01 versus control group, ### P<0.001 versus STZ-NA group, †, P<0.01 versus STZ-NA group, ## p<0.05 versus STZ-NA group, n.s., p>0.05 versus STZ-NA group.

**Table 2. Liver NO levels, serum NOS levels and plasma LCAT activity of the studied groups.**

| Variable                  | Control       | STZ-NA       | D Met       | DE           | DEMet        |
|---------------------------|---------------|--------------|-------------|--------------|--------------|
| NO (μmol/mg protein)      | 0.78±0.2      | 0.58±0.1***  | 0.60±0.1##  | 0.51±0.1##   | 0.52±0.1##   |
| NOS (pmol/ml)             | 85.3±8.4      | 75.9±4.9##   | 80.1±5.5##  | 84.1±5.2##   | 81.8±4.1##   |
| LCAT (μmol/ml/saat)       | 6.28±1.3      | 4.29±1.1***  | 5.08±0.7##  | 4.44±0.9##   | 4.51±1.2##   |

*** P<0.001 versus control group, ** P<0.01 versus control group, ### P<0.001 versus STZ-NA group, †, P<0.01 versus STZ-NA group, ## p<0.05 versus STZ-NA group, n.s., p>0.05 versus STZ-NA group.
effect of metformin treatment. On the other hand, metformin treatment had no effect on cholesterol levels while exercise decreases it. However, neither metformin treatment nor exercise had effect on TG levels. Maybe the reason of this ineffectiveness was due to the shortness of the experimental period. There was no enough time for the appearance of the decrease.

It is generally accepted that, improved glycoregulation will result in normalization of elevated lipid levels (Iızuka, 1989). LCAT is an important enzyme involved in HDL metabolism. LCAT increases HDL size by transferring 2-acyl groups from lecithin or phosphatidylethanolamine to free cholesterol. LCAT activity therefore results in the generation of cholesteryl esters that are retained in the core of HDL particles. Hyperglycemia results in non-enzymatic glycation of various proteins. Glycation of HDL on serine residues in its most abundant protein moiety, Apo A-I, causes conformational changes eventually resulting in reduced LCAT activity (Nakhjavani et al., 2008). It is well known that HDL and LCAT activity responses to glycemic control in diabetic patients depending on the type of treatment (Iızuka, 1989). In the present study, LCAT activity was significantly decreased in STZ-NA group compared to the control group. There were no statistical differences between STZ-NA group and the treatment groups although LCAT activity was increased in the treatment groups. Probably, the duration of treatment was not adequate for the response of diabetic control. LCAT contributes to maintaining a concentration gradient of free cholesterol between the cell membrane and plasma, and defective LCAT activity might result in an increase in the plasma cholesterol concentration. In our study, similar to the LCAT activity, the Apo A-I levels were not increased probably again due to the insufficient experimental period. The decrease in LCAT reactivity could affect the reverse cholesterol transport of HDL and thereby contribute to the atherosclerotic process in diabetics (Kiziltunc et al., 1997). In our study, the cholesterol levels were decreased in treatment groups. High plasma TG and changes in LCAT are probably due to the abnormalities in HDL composition (Kingwell et al., 2002). In our study, when compared to control group there was a decrease in the levels of HDL and Apo A-I in STZ-NA group, supporting that data obtained by decrease in the activity of LCAT in type 2 diabetes can have negative influences on HDL and Apo A-I levels (Nobecourt et al., 2007).

Contrary to our study, Lehman et al. (2001) showed that physical activity in patients with type 2 diabetes led to an overall increase in LCAT. Exercise causes production of reactive oxygen species (ROS) (Santangelo et al., 2003). Abnormally high levels of free radicals, lipid peroxidation and simultaneous decline in antioxidant defense mechanism can lead to damage of cellular organelles and enzymes (Saravanan and Pari, 2006).

In the present study, when compared with control group, STZ-NA group showed a significant decrease in liver NO levels. Decreased NO function is multifactorial, involving both impaired endothelial production of NO and accelerated NO inactivation. The diminished NO synthesis associated with type 2 diabetes has been attributed to uncoupling of receptor-mediated signal transduction (Angeline et al., 2011), to a relative deficiency of L-arginine and to a decrease availability of eNOS cofactor, BH₄ (Wu and Meininger, 2009; Angeline et al., 2011). The reduced NO bioavailability is caused largely by decreased NO production, which may result from accumulation of asymmetric dimethylarginine (ADMA) or reduced bioavailability of L-arginine (Gates et al., 2007). ADMA is major endogenous inhibitor of NOS and therefore NO bioavailability. Higher levels of ADMA are associated with insulin resistance and diabetes (Kanazawa et al., 2010).

The liver is the main organ of oxidative and detoxifying process. In many diseases, biomarkers of oxidative stress are elevated in the liver at an early stage (Dias et al., 2005). NO is rapidly inactivated by O₂ and it has been reported that an enhanced formation of O₂ radical may be involved in the accelerated breakdown of NO. Metformin has antioxidant activity which is independent of its effect on insulin activity. The protective effect of metformin against oxidative stress may prevent the breakdown of nitric oxide. Moreover in the recent studies, metformin is reported to increase NO activity without increasing nitric oxide expression in type 2 diabetic n-STZ model (Majithiya and Balaraman, 2006). This increase in NO activity may be due to the reduction in oxidative stress by metformin. In our study, STZ-NA administration decreased NO and NOS levels. But any of the treatment skills did not increase NO levels while exercise has positive effect on NOS levels. The deficiency on the increase of NO levels may be attributed to the insufficient dose of metformin or the insufficient time for the emergence of increase.

Increase in the formation of advanced glycation end products (AGEs) due to hyperglycemia have the capacity to suppress the expression of constitutive nitric oxide synthase activity and also quench NO, contributing to decreased levels of NO in diabetes (Mohan and Das, 2000). Free fatty acids, elevated in insulin resistant states, also inhibit eNOS activity and causes decreases in NO production. Sartoretto et al. (2005) showed that metformin treatment ameliorated total NOS activity without correcting the increased blood glucose. In the present study, metformin did not ameliorate the serum NOS activity while it decreases blood glucose. On the other hand, exercise caused an increase in both exercise and exercise and metformine groups, by supporting Kurowska, who reported that acute exercise increases NOS activity and NO release in rat experiments (Kurowska, 2002). Our study showed a significant increase in serum NOS level in DE and DEMet groups compared to STZ-NA group.

In conclusion, these results suggested that both
administration of metformin and exercise intervention decreased serum glucose levels independently. However, the surprising result that was found was that exercise intervention did not optimize the result of metformin treatment. The other finding of this study was that exercise intervention increased NO level but exercise combined with metformin was not better than exercise alone. Thus, it appears from the present study that metformin and exercise combination has no effect. Longitudinal studies are required to confirm our results.

ACKNOWLEDGEMENT

This study was supported by Eskisehir Osmangazi University Scientific Research Commission. Contract grants number 2006-11.

REFERENCES

Anurag P, Anuradha CV (2002). Metformin improves lipid metabolism and attenuates lipid peroxidation in high fructose-fed rats. Diabetes. Obes. Metab., 4: 36-42.

Angeline T, Krittiha HR, Isabel W, Asirvatham AJ, Poornima A (2011). Endothelial nitric oxide synthase gene polymorphism (G894T) and diabetes melitus (type II) among south indians. Oxid. Med. Cell Longev, doi:10.1155/2011/462607.

Bailey CJ (2011). Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol. Sci., 32:63-71.

Blevins T (2010). Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. Postgrad. Med., 122: 172-83.

Choi SB, Jang JS, Hong SM, Jun DW, Park S (2006). Exercise and dexamethasone oppositely modulate b-cell function and survival via independent pathways in 90% pancreatectomized rats. J. Endocrinol., 190: 71-482.

Copp SW, Hageman KS, Behnke BJ, Poole DC, Musch TI (2010). Effects of type II diabetes on *exercising skeletal muscle blood flow in the rat. J. Appl. Physiol., 109: 1347–1353.

Cortas NK, Waidk NW (1990). Determination of inorganic nitrate in serum by urine by a kinetic cadmium-reduction method. Anal. Chem., 62: 1440-1443.

Dias AS, Porawski M, Alonso M, Marroni N, Collado PS, Gonzalez-Gallo J (2005). Quercetin decreases oxidative stress, NF-KB activation, and iNOS overexpression in liver of streptozotocin-induced diabetic rats. J. Nutr., 135: 2299-2304.

El-Mahmoudy A, Shimizu Y, Shinya T, Matsuyama H, El-Sayed M, Takewaki T (2005). Successful abrogation by thymoquinone against induction of diabetes mellitus with streptozotocin via nitric oxide inhibitory mechanism. Int. Immunopharmacol., 5: 195–207.

Futter LE, Al-Swayeh OA, Moore PK (2001). A comparison of the effect of nitroparacetamol and paracetamol on liver injury. Br. J. Pharmacol., 132: 10-12.

Gao Y (2010). The multiple actions of NO. Eur. J. Physiol., 459:829–839.

Gates PE, Boucher ML, Silver AE, Monahan KD, Seals DR (2007). Impaired flow-mediated dilation with age is not explained by L-arginine bioavailability or endothelial asymmetric dimethylarginine *protein expression. J. Appl. Physiol., 102: 63–71.

Goto T, Onomis S, Khedara A, Kato N, Ogawa H, Yanagit T (1999). Feeding the nitric oxide synthase inhibitor L-N^3 nitroarginine elevates serum very low density lipoprotein and hepatic triglyceride synthesis in rats. J. Nutr. Biochem., 10: 274-277.

Hrabak A, Szabo A, Bajor T, Korner A (2006). Differences in the nitric oxide metabolism in streptozotocin-treated rats and children suffering from type 1 diabetes. Life Sci., 78: 1362-1370.

Izuka T (1989). Effect of anti-diabetic treatment on high density lipoprotein-comosition and lecithin: cholesterol acyltransferase activity- a comparison between insulin, sulfonylurea and diet alone treatments. Jpn. J. Med., 28: 457-461.

Kanazawa I, Yano S, Yamaguchi S, Notsu Y, Nabika T, Sugimoto T (2010). Relationships between dimethylarginine and the presence of vertebral fractures in type 2 diabetes mellitus. Clin. Endocrinol., 73: 463-468.

Katakam PV, Ujheldy MR, Hoeing M, Miller AW (2000). Metformin improves vascular function in insulin-resistance rats. Hypertension, 35: 108-112.

Kiziltunc A, Akay F, Polat F, Kuskay S, Sahin YN (1997). Reduced lecithin:cholesterol acyltransferase (LCAT) and Na^+, K^-ATPase activity in diabetic patients. Clin. Biochem., 30:177-182.

Kingwell B (2000). Nitric oxide as a metabolic regulator during exercise: effects of training in health and disease. Clin. Exp. Pharmacol. Physiol., 27: 239-250.

Kingwell BA, Formosa M, Mulhmann M, Braddy SJ, McConel GK (2002). Nitric oxide synthase inhibition reduces glucose uptake during exercise in individuals with type 2 diabetes more than control subjects. Diabetes, 51: 2572-2580.

Kurowska EM (2002). Nitric oxide therapies in vascular diseases. Curr. Pharm. Des., 8: 155-166.

Lampman RM, Schteingart DE (1991). Effects of exercise training on glucose control, lipid metabolism, and insulin sensitivity in hyperglycemic rats. Metab. 30: 37-44.

Li HT, Xu X, Dafev AK, Wang J (2011). Antihyperglycemic Effects of Baicalin on Streptozotocin – Nicotinamide induced Diabetic Rats. Phytother., Res., 25: 189-94.

Ma R, Sun M, Yang Z (2011).Inhibition of nitric oxide synthase lowers fatty acid oxidation in preeclampsia-like mice at early gestational stage. Chin. Med. J., 124: 3141-3147.

Majithiya JB, Balaraman R (2006). Metformin reduces blood pressure and restores endothelial function in aorta of streptozotocin-induced diabetic rats. Life Sci., 78: 2515-2624.

Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, Novelli M, Ribes G (1998). Experimental NIDDM. Development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes, 47: 224-229.

Merry TL, McConell GK (2009). Skeletal muscle glucose uptake during exercise: a focus on oxidative and glycolytic species and nitric oxide signaling. IUBMB Life, 6: 479–484.

Mohan IK, Das UN (2000). Effect of L-arginine-nitric oxide system on the metabolism of essential fatty acids in chemical-induced diabetes mellitus. Prostaglandins. Leukot. Essent. Fatty. Acids, 62: 35-46.

Nagasaki T, Akanuma Y (1977). A new colorimetric method for the determination of plasma lecithin-cholesterol acyltransferase activity. Clin. Chim. Acta, 75: 371-375.

Nakhiavan J, Esteghamati A, Esfahanian F, Ghanei A, Hashadi A, Hashemi S (2008). HbA1c negatively correlates with LCAT activity in type 2 diabetes. Diabetes Res. Clin. Pract., 81: 38-41.

Newsholme P, Hooman De Bittencourt PI, O’ Hagan C, De Vito G, Murphy C, Krause MS (2010). Exercise and possible molecular mechanisms of protection from vascular disease and diabetes: the *central role of ROS and nitric oxide. Clin. Sci., 118: 341–349.

Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Newsholme P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, Novelli P, Fabregat ME, Fernandez A (2004). Microvascular complications of diabetes mellitus. Curr. Diabetes Rev., 175: 57-67.

Novelli P, Pocai A, Lajoix AD, Befy P, Bezzi D, Marchetti P, Gross R, Maiselo P (2004). Alteration of β-cell constitutive NO synthase activity is involved in the abnormal insulin response to arginine in a...
new rat model of type 2 diabetes. Moll. Cell. Endocrinol., 219: 77-82.
Okamoto T, Kanemoto N, Ohbuchi Y, Okano M, Fukui H, Sudo T (2008). Characterization of STZ-induced type 2 diabetes in zucker fatty rats. Exp. Anim., 57: 335–345.
Ozbayer C, Kurt H, Kalender K, Ozden H, Gunes HV, Basaran A, Cakmak EA, Civi K, Kalender Y, Degirmenci I (2011). The effects of Stevia rebaudiana (Bertoni) extract and N-Nitro-l-Arginine on renal function and ultrastructure of kidney cells in experimental type 2 diabetes. J. Med. Food, 14: 1-8.
Reaven G, Chang F (1981). Effect of exercise training on the metabolic manifestations of streptozotocin induced diabetes in rat. Diabetologia, 21: 415-417.
Santangelo L, Cigliano L, Montefusco A, Spagnuolo MS, Nigro G, Golino P, Abrescia P (2003). Evaluation of the antioxidant response in the plasma of healthy or hypertensive subjects after short-term exercise. J. Hum. Hypertens, 17: 791-798.
Saravanan R, Pari L (2006). Effect of a novel insulinotropic agent, succinic acid monoethyl ester, on lipids and lipoproteins levels in rats with streptozotocin-nicotinamide-induced type 2 diabetes. J. Biosci., 31: 581-587.
Sartoretto JL, Melo GAN, Carvalho MHC, Nigro D, Passaglia RT, Scavone C, Cuman RKN, Fortes B (2005). Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin-induced diabetic rats increasing NOS activity, but not NOS expression. Life Sci., 77: 2676-2689.

Tahara A, Yokono AM, Nakano R, Someya Y, Shibasaki M (2008). Hypoglycemic effects of antidiabetic drugs in streptozotocin nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats. Basic. Clin. Pharmacol. Toxicol., 103: 560–568.
Tang T, Reed MJ (2001). Exercise adds to metformin and acarbose efficacy in db/db mice. Metabolism, 50: 1049-1053.
Valeri C, Pozzilli P, Leslie D (2004). Glucose control in diabetes. Diab. Metab. Res. Rev., 20: S1-8.
Wu G, Meininger CJ (2009), Nitric oxide and vascular insulin resistance. Biofactors, 35: 21-27.
Yi SS, Hwang IK, Yoo KY, Park OK, Yu J, Yan B, Kim JY, Kim YN, Pai T, Song W, Lee J, Won MH, Seong JK, Yoon YS (2009). Effects of treadmill exercise on cell proliferation and differentiation in the subgranular zone of the dentate gyrus in a rat model of type II diabetes. Neurochem. Res., 34: 1039–1046.
Zand J, Lanza F, Garg HK, Bryan NS (2011). All-natural nitrite and nitrate containing dietary supplement promotes nitric oxide production and reduces triglycerides in humans. Nutr. Res., 31: 262-269.